1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsRural Communities Opioid Response Program (RCORP) - Implementation is sponsored by Health Resources and Services Administration (HRSA). This program aims to strengthen and expand substance use disorder (SUD), including opioid use disorder (OUD), prevention, treatment, and recovery services in high-risk rural communities.
Get alerted about grants like this
Save a search for “Health Resources and Services Administration (HRSA)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Rural Communities Opioid Response Program (RCORP)-Planning Rural Communities Opioid Response Program (RCORP)-Planning Agency: Health Resources and Services Administration Assistance Listings: 93. 690 -- Rural Communities Opioid Response Programs Last Updated: May 29, 2026 View version history on Grants.
gov Rural Communities Opioid Response Program (RCORP)-Planning supports organizations in rural communities to build the partnerships and foundational capacity needed to develop, implement and sustain a comprehensive system of substance use disorder (SUD) and related services. RCORP’s focus is on opioid misuse and its impact on rural America.
However, HRSA recognizes that people who misuse opioids often struggle with other substances as well, including alcohol. Individuals struggling with SUD, including opioid use disorder (OUD), need a continuum of mental, behavioral, and related social supports. RCORP-Planning helps address these needs in a comprehensive way.
This program is intended for rural communities that may find the logistics or requirements of larger, more complex federal grant programs to be barriers to accessing start-up support. Funding will serve as a critical first step to creating SUD service systems that make care easy to access, strengthen the behavioral health workforce, and have strong community buy-in.
It will help prepare communities to provide sustainable prevention, treatment, recovery, and other supportive services that: reduce substance use initiation and misuse, address the mental, behavioral, and psychosocial needs of people who use illicit substances or misuse alcohol, or are in recovery from substance use problems, and reduce disease and death related to substance use problems, including OUD, in high-risk rural communities.
The intent of this program is to fund planning activities only. Funds may not be used for direct service delivery.
Federally recognized Native American tribal governments Public and Indian housing authorities Special district governments City or township governments For-profit organizations other than small businesses Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Private institutions of higher education Public and state institutions of higher education Independent school districts You can apply if you are a domestic public or private, non-profit or for-profit entity.
"Domestic" means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau. Grantor contact information ruralopioidresponse@hrsa. gov ruralopioidresponse@hrsa.
gov No documents are currently available. Link to additional information https://www. hrsa.
gov/rural-health/opioid-response Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
Based on current listing details, eligibility includes: Domestic public or private, non-profit or for-profit entities, including faith-based and community-based organizations, tribes, and tribal organizations. Applicants must be part of broad, multi-sectoral consortia. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies by award (HRSA awarded $19,182,411 to 58 grantees in FY25) Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.